Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Loss of hematopoietic progenitors heterogeneity is an adverse prognostic factor in lower-risk myelodysplastic neoplasms.
Dussiau C, Comont T, Knosp C, Vergnolle I, Bravetti C, Canali A, Houvert A, Largeaud L, Daveaux C, Zaroili L, Friedrich C, Boussaid I, Zalmai L, Almire C, Rauzy O, Willems L, Birsen R, Bouscary D, Fontenay M, Kosmider O, Chapuis N, Vergez F. Dussiau C, et al. Among authors: kosmider o. Leukemia. 2024 May;38(5):1131-1142. doi: 10.1038/s41375-024-02234-6. Epub 2024 Apr 4. Leukemia. 2024. PMID: 38575672 Free PMC article.
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).
Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F, Viguié F, Quesnel B, Beyne-Rauzy O, Solary E, Vey N, Hunault-Berger M, Fenaux P, Mansat-De Mas V, Delabesse E, Guardiola P, Lacombe C, Vainchenker W, Preudhomme C, Dreyfus F, Bernard OA, Birnbaum D, Fontenay M; Groupe Francophone des Myélodysplasies. Kosmider O, et al. Blood. 2009 Oct 8;114(15):3285-91. doi: 10.1182/blood-2009-04-215814. Epub 2009 Aug 7. Blood. 2009. PMID: 19666869 Free article.
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.
Kosmider O, Gelsi-Boyer V, Ciudad M, Racoeur C, Jooste V, Vey N, Quesnel B, Fenaux P, Bastie JN, Beyne-Rauzy O, Stamatoulas A, Dreyfus F, Ifrah N, de Botton S, Vainchenker W, Bernard OA, Birnbaum D, Fontenay M, Solary E; Groupe Francophone des Myélodysplasies. Kosmider O, et al. Haematologica. 2009 Dec;94(12):1676-81. doi: 10.3324/haematol.2009.011205. Epub 2009 Oct 1. Haematologica. 2009. PMID: 19797729 Free PMC article.
Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.
Nibourel O, Kosmider O, Cheok M, Boissel N, Renneville A, Philippe N, Dombret H, Dreyfus F, Quesnel B, Geffroy S, Quentin S, Roche-Lestienne C, Cayuela JM, Roumier C, Fenaux P, Vainchenker W, Bernard OA, Soulier J, Fontenay M, Preudhomme C. Nibourel O, et al. Among authors: kosmider o. Blood. 2010 Aug 19;116(7):1132-5. doi: 10.1182/blood-2009-07-234484. Epub 2010 May 20. Blood. 2010. PMID: 20489055 Free article.
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Adès L, Fenaux P, Fontenay M; Groupe Francophone des Myelodysplasies (GFM). Itzykson R, et al. Among authors: kosmider o. Leukemia. 2011 Jul;25(7):1147-52. doi: 10.1038/leu.2011.71. Epub 2011 Apr 15. Leukemia. 2011. PMID: 21494260
TET2 mutations in secondary acute myeloid leukemias: a French retrospective study.
Kosmider O, Delabesse E, de Mas VM, Cornillet-Lefebvre P, Blanchet O, Delmer A, Recher C, Raynaud S, Bouscary D, Viguié F, Lacombe C, Bernard OA, Ifrah N, Dreyfus F, Fontenay M; GOELAMS Investigators. Kosmider O, et al. Haematologica. 2011 Jul;96(7):1059-63. doi: 10.3324/haematol.2011.040840. Epub 2011 Apr 20. Haematologica. 2011. PMID: 21508122 Free PMC article.
Leukemic phase of follicular lymphomas: an atypical presentation.
Al-Nawakil C, Kosmider O, Stern MH, Manié E, Bardet V, Leblond V, Park S, Dreyfus F, Bouscary D, Tamburini J. Al-Nawakil C, et al. Among authors: kosmider o. Leuk Lymphoma. 2011 Aug;52(8):1504-8. doi: 10.3109/10428194.2011.574753. Epub 2011 May 17. Leuk Lymphoma. 2011. PMID: 21585282
Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes.
Le Pogam C, Krief P, Beurlet S, Soulié A, Balitrand N, Cassinat B, Cavé H, Kosmider O, Setterblad N, Leboeuf C, Sarda-Mantel L, Hervatin F, Merlet P, Noguera ME, Janin A, Pla M, Fontenay M, Adès L, Fenaux P, Chomienne C, Padua RA, Omidvar N. Le Pogam C, et al. Among authors: kosmider o. Leuk Res. 2013 Mar;37(3):312-9. doi: 10.1016/j.leukres.2012.10.018. Epub 2012 Nov 12. Leuk Res. 2013. PMID: 23153525
Sustained leukemia-free state and molecular response to sorafenib in a patient with chronic myelomonocytic leukemia in transformation driven by homozygous FLT3-ITD malignant hematopoiesis.
Kosmider O, Chapuis N, Kaltenbach S, Coriat R, Boudou Rouquette P, Willems L, Chesnais V, Radford-Weiss I, Bardet V, Mayeux P, Tamburini J, Fontenay M, Bouscary D. Kosmider O, et al. Clin Lymphoma Myeloma Leuk. 2013 Jun;13(3):347-50. doi: 10.1016/j.clml.2012.11.007. Clin Lymphoma Myeloma Leuk. 2013. PMID: 23246161 No abstract available.
154 results